News from Absolutely PR and its clients. Absolutely PR specializes in media relations, the strategies and tactics necessary to achieve impactful editorial placements in the national/international, trade press local and social media. Follow tweets at @AbsolutelyPR or call for information 303.669.3558
"The Primavera Group will assume media relations and strategic public relations for the Colorado BioScience Association (CBSA) following the departure of Absolutely Public Relations in that role due to the retirement of Maggie Holben, Absolutely PR’s owner...
...'We’re thrilled to welcome Sarah and her associates at the Primavera Group to our CBSA team,' said April Giles, CBSA president and CEO...
...Holben said she is only “semi-retiring” from the PR business and will keep Absolutely PR open but will take on fewer projects to allow for more time for family and travel."
Kevin Smith, president and CEO of the Colorado Institute for Drug, Device and Diagnostic Development, poses at his office Aug. 29, 2011, near the Anschutz Medical Campus in Aurora. (Heather L. Smith/Aurora Sentinel)
The Primavera Group will assume the media relations and strategic public relations contract for the Colorado BioScience Association (CBSA) beginning January 5, 2015. The announcement is made by CBSA President and CEO April Giles, who says, "We’re thrilled to welcome Sarah and her associates at the Primavera Group to our CBSA team. They will be taking over from Absolutely PR’s Owner/Principal Maggie Holben who is retiring as CBSA's PR Consultant after more than ten years of service to the organization as a board member, contract PR resource and volunteer. In 2006, Absolutely PR was named CBSA Partner of the Year during the annual Awards Dinner. While we will miss Maggie, we are excited for all that will unfold under Sarah and her team’s direction going forward.”
Primavera Group is a Colorado-based brand development and integrated strategic marketing communications company that serves clients in technology, communications, business consulting and other growth industries. The team develops high-impact strategies, innovative solutions and persuasive content to communicate clients’ stories and compel audiences to action. Their client list spans established Fortune 50 companies to promising start ups.
“Our clients turn to us for crisp thinking, quick execution and our senior-level expertise. We believe the proof is in our performance, and we are proud of our 100% repeat engagement track record. We’re the firm that our clients count on time and again to generate results. In turn, our Primavera team looks forward to representing Colorado’s thriving Bioscience Industry,” Eder said.
In the bioscience space, Primavera has worked with CBSA member company, Sharklet Technologies, for the past seven years, achieving key media placements internationally, nationally and locally for the Colorado-based medical technology company. Most notably Primavera has placed Sharklet on a PBS Nova segment, CBS News Sunday Morning, The Wall Street Journal, Fast Company, Wired, Discover Magazine, Inc Magazine, Popular Science, FierceBiotech, European Medical Device Manufacturer, the Discovery Channel and, the Jeopardy game show where Sharklet was included as a featured answer. For more information, visit http://sharklet.com/about-us/in-the-news and www.theprimaveragroup.com.
“I’ve worked with Sarah over the years and I’m simply thrilled to be able to pass CBSA’s PR baton to her and her team. I’m confident Sarah’s business and PR acumen is exactly what CBSA needs to take our organization to the next level in its awareness growth curve. While I’m retiring as CBSA’s PR consultant, I’m only semi-retiring from the PR business. I’ll continue to keep my Absolutely PR consulting firm open in the future, but will be taking on projects of a lesser scope than the CBSA contract to allow for more travel and time with my family,” Holben explains. For more information, visit: http://www.absolutelypr.com.
Colorado attained a number of key financings, acquisitions and expansions in its bioscience industry during 2014. April Giles, President and CEO of the Colorado BioScience Association says: "We’ve seen a number of exciting deals come to fruition in our Colorado bioscience community during 2014, which strengthens our state’s position as a national industry leader. We’re thrilled that CBSA has continued to play a significant role in promoting Colorado as a dynamic region for bioscience innovation and investment.”
Highlighted Financings and Acquisitions in 2014 Include: * Terumo BCT broke ground on a 120,000-square-foot global headquarters building – April 1, 2014
Terumo BCT is building a 120,000-square-foot Global Headquarters building on its Lakewood campus. In 2015,
when the building opens, Terumo BCT will occupy 90,000 square feet, leaving the additional space available for future growth and development. When complete, it will accommodate an estimated 400 associates. http://coloradocommunitymedia.com/stories/A-global-home,151084
* BioScience Park Center 2 groundbreaking adding 112,000 square foot building – April 4, 2014
The Fitzsimons Redevelopment Authority (FRA) and CU's Bioengineering program, design a multipurpose building for education, research and clinical care, with an added entrepreneurial element of private biosciences companies. Bioengineering students will have classes on the first two floors of the four-story building, and from there, the students will move up a floor and practice what they have learned and then move up again to begin their own commercial bioscience company on the top floor. http://www.ucdenver.edu/about/newsroom/newsreleases/Pages/Bioscience-2-groundbreaking-April-2014.aspx
* Clovis Oncology to offer $200M in convertible senior notes in private placement to investors – Sept 3, 2014
Boulder based Clovis Oncology Inc. announced it intended to offer $200 million aggregate principal amount of its convertible senior notes due 2021 in a private placement to qualified international buyers.
* InDevR Wins $14.7M Barda Contract for Cutting-Edge Influenza Diagnostic – September 15, 2014
Boulder based InDevR announced that it signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to complete product development of their unique influenza diagnostic, FluChip-8G, which is capable of rapidly genotyping influenza viruses directly from clinical samples. http://www.marketwired.com/press-release/-1947252.htm
* N30 Pharmaceuticals Secures $30 Million in Oversubscribed Crossover Financing – November 19, 2014
Boulder based N30 Pharmaceuticals, Inc. (“N30 Pharma”), a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis (CF), has raised $30 million in a mezzanine round of financing. Proceeds from the financing will primarily be used to advance the Company’s clinical trial program. New investors include Wellington Management, RA Capital Management, LLC, Jennison Associates LLC (on behalf of certain clients), Rock Springs Capital Management LP, and Sabby Management, LLC, who joined existing investor, Deerfield Management Company. http://www.prnewswire.com/news-releases/n30-pharmaceuticals-secures-30-million-in-oversubscribed-crossover-financing-283193921.html